Tags

Type your tag names separated by a space and hit enter

Thiomersal as a vaccine preservative.

Abstract

Thiomersal poses a theoretical low risk of neurodevelopmental toxicity in infants. The known risk of morbidity and mortality from vaccine-preventable diseases and of contaminated multidose vaccine vials far outweigh any potential risk posed by thiomersal. However, with the weight of public opinion against the use of mercury of any sort, WHO and other agencies have begun the process of reducing and removing thiomersal from vaccines. In the short term (the next 3 years), modifications to existing strategies will result in a reduction in exposure to thiomersal. Over the long term (beyond 3 years), efforts will be focused on new vaccine-delivery technologies, alternative preservatives and combination vaccines, further reducing and eventually, perhaps, eliminating thiomersal from vaccines.

Source

Releve epidemiologique hebdomadaire 75:2 2000 Jan 14 pg 12-6

MeSH

Adult
Adverse Drug Reaction Reporting Systems
Child
Child, Preschool
Dose-Response Relationship, Drug
Female
Humans
Infant
Infant, Newborn
Male
Pregnancy
Preservatives, Pharmaceutical
Thimerosal
Vaccines

Pub Type(s)

Journal Article

Language

eng fre

PubMed ID

10697462

Citation

"Thiomersal as a Vaccine Preservative." Releve Epidemiologique Hebdomadaire, vol. 75, no. 2, 2000, pp. 12-6.
Thiomersal as a vaccine preservative. Wkly Epidemiol Rec. 2000;75(2):12-6.
(2000). Thiomersal as a vaccine preservative. Releve Epidemiologique Hebdomadaire, 75(2), pp. 12-6.
Thiomersal as a Vaccine Preservative. Wkly Epidemiol Rec. 2000 Jan 14;75(2):12-6. PubMed PMID: 10697462.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thiomersal as a vaccine preservative. PY - 2000/3/4/pubmed PY - 2000/3/25/medline PY - 2000/3/4/entrez SP - 12 EP - 6 JF - Releve epidemiologique hebdomadaire JO - Wkly. Epidemiol. Rec. VL - 75 IS - 2 N2 - Thiomersal poses a theoretical low risk of neurodevelopmental toxicity in infants. The known risk of morbidity and mortality from vaccine-preventable diseases and of contaminated multidose vaccine vials far outweigh any potential risk posed by thiomersal. However, with the weight of public opinion against the use of mercury of any sort, WHO and other agencies have begun the process of reducing and removing thiomersal from vaccines. In the short term (the next 3 years), modifications to existing strategies will result in a reduction in exposure to thiomersal. Over the long term (beyond 3 years), efforts will be focused on new vaccine-delivery technologies, alternative preservatives and combination vaccines, further reducing and eventually, perhaps, eliminating thiomersal from vaccines. SN - 0049-8114 UR - https://www.unboundmedicine.com/medline/citation/10697462/Thiomersal_as_a_vaccine_preservative_ L2 - https://medlineplus.gov/immunization.html DB - PRIME DP - Unbound Medicine ER -